In adults with type 1 diabetes, hypoglycemia occurred in 12% of exercise sessions with glucagon versus 39% with placebo (P < 0.0001).
In plain wordsWith the same insulin reduction, glucagon reduced exercise hypoglycemia versus placebo in adults with type 1 diabetes.
- Peptide
- Glucagon
- Outcome
- DecreaseLevel 1 hypoglycemia: arm A
- Study
n: not reported in source
- Comparator
- Placebo with 50% basal insulin reduction
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 150 µg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
- Level 1 hypoglycemia incidence
- 12%
- arm A, glucagon 150 ug with 50% basal reduction
- Level 1 hypoglycemia incidence
- 39%
- arm B, placebo
- P value
- < 0.0001
- arm A vs arm B
Source sentences
For all exercise sessions in the outpatient phase (n = 795), incidence of level 1 hypoglycemia was lower in both glucagon arms (A, 12% [P < 0.0001]; C, 16% [P = 0.0032]) than in the placebo arm (B, 39%).
3 context sentences(design, population, supporting numbers)
Individuals initially participated in the in-clinic training phase for which they were randomly assigned to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate.
Completers were then rerandomly assigned in the 12-week outpatient investigational phase: arm A, B, or open-label C, 150 µg glucagon alone.
Of 48 participants who completed the training phase, 45 continued to the outpatient phase.